The Next Wave of Specialty Drugs: What Comes After Ozempic?

The next wave of specialty drugs is here—and it’s redefining what “specialty” even means. This webcast will explore key therapies in the near-term pipeline, how plan sponsors can evaluate value versus cost and how plan design strategies need to evolve as these treatments become more widespread. Key takeaways include:

• What are key drugs in the near-term pipeline that plans need to be thinking about in advance of their arrival: oral GLP-1s and next generation incretin combinations, Alzheimer’s biologic therapies, gene/RNA-based therapies with broader indications, etc.?
• How do plans evaluate incremental benefit vs. cost? For example, how does a plan deal with the next generation GLP-1 combination product that might drive slightly more weight loss than existing therapies but at a higher cost?
• What happens when “specialty” drugs are no longer special? As these therapies become more ubiquitous in plan experiences, what are best practices with respect to plan design to ensure responsible utilization of finite plan resources?